Monday, November 7, 2016
Investigation..
FBI Director James Comey told lawmakers Sunday the agency hasn't changed its opinion that Hillary Clinton should not face criminal charges after a review of new emails.
Comey dropped a bombshell on the presidential race when he sent a letter to Congress saying the FBI had discovered emails in a separate investigation that could be connected to the now-closed probe of whether Clinton mishandled classified information. The move infuriated Democrats and emboldened Republican nominee Donald Trump.
With Wikileaks releasing 2,073 Podesta emails in part 32 of its ongoing dump of hacked Hillary's campaign chairman emails, largely overshadowed by the FBI "scandal" which has now fully blown over.
Director Comey first zigged, announcing in a cryptic statement he was reopening a probe into Clinton's email server, only to zag later when reported it had found nothing material in the 650,000 emails found on Anthony Weiner's laptop.
Waiting for Wiki's Leaks .... There is more where this come from... Just a thought.
Sunday, November 6, 2016
Meathead
The acclaimed filmmaker, formerly known as 'Meathead' on 'All in the Family,' is a huge Clinton supporter so it was a shock on Nov. 4 when his Twitter account sent out a "Go Trump" tweet. He was hacked, he said in another tweet. "Disgusting! He is utter garbage. Go HRC!" He's seen here at the Toronto Film Festival in September 2016.
Saturday, November 5, 2016
Friday, November 4, 2016
Choose ?..
Findings culled from a new method for aggregating and making sense of data in the FDA’s Adverse Event Reporting System (AERS) present a surprising glimpse at the postmarketing adverse event data for statins.
The study found a class-wide variation in muscle-related adverse event reports. The results linked rosuvastatin (Crestor, AstraZeneca) with the highest percentage risk in 6 categories, including myopathy (general), myalgia, myositis, rhabdomyolysis, joints and tendons, muscle atrophy and injury, and muscle coordination and weakness. Pravastatin (Pravachol, Bristol-Myers Squibb) and lovastatin (Mevacor, Merck) demonstrated the best muscle-related safety profile.
“The results were surprising because in the literature it’s generally regarded that Crestor is very safe ... and Crestor, across the board, seemed to be linked to more adverse events in the categories that we searched than the other statin drugs” said Keith Hoffman, PhD, vice president, Scientific Affairs, AdverseEvents, Inc.
Through RxFilter, the company identified more than 150,000 muscle-related adverse event reports in 6 categories linked to statins between January 1, 2004 and March 31, 2011. The drugs included atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), pravastatin (Pravachol), rosuvastatin (Crestor), fluvastatin (Lescol), as well as generic equivalents and foreign designations. Percent risk calculations were determined based on the number of primary suspect adverse events linked to each statin, divided by an estimated number of patients exposed to the drugs during the study period. A ranked risk measure was used to calculate within-drug comparisons.
The results indicated that Crestor had the highest percent risk in each of 6 adverse event categories examined, while Pravachol and Mevacor appeared to have the least.
The company’s database is now online at www.adverseevents.com.
Thursday, November 3, 2016
Subscribe to:
Posts (Atom)